2,600 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 2,600 shares of the biopharmaceutical company's stock, valued at approximately $612,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nordea Investment Management AB boosted its holdings in shares of Alnylam Pharmaceuticals by 6.7% during the 4th quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company's stock valued at $2,417,000 after purchasing an additional 637 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock valued at $1,532,000 after buying an additional 58 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Alnylam Pharmaceuticals by 2.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company's stock valued at $624,000 after buying an additional 63 shares during the last quarter. Pallas Capital Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 2.6% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,408 shares of the biopharmaceutical company's stock valued at $802,000 after buying an additional 87 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Alnylam Pharmaceuticals by 13.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after acquiring an additional 2,285 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares of the company's stock, valued at $3,240,344.36. The trade was a 10.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,561 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the completion of the transaction, the chief marketing officer now directly owns 13,537 shares in the company, valued at $3,454,236.29. This represents a 10.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,392 shares of company stock valued at $1,875,627 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 0.3%

Alnylam Pharmaceuticals stock traded up $0.69 during mid-day trading on Wednesday, reaching $267.55. 700,397 shares of the company were exchanged, compared to its average volume of 905,029. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a market cap of $34.89 billion, a P/E ratio of -123.29 and a beta of 0.17. The business has a fifty day moving average of $251.33 and a 200 day moving average of $253.69. Alnylam Pharmaceuticals, Inc. has a 12-month low of $144.73 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period in the prior year, the business earned ($0.16) EPS. Alnylam Pharmaceuticals's revenue was up 20.2% compared to the same quarter last year. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ALNY shares. Needham & Company LLC reiterated a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. HC Wainwright reaffirmed a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Scotiabank increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Finally, Morgan Stanley cut their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.